InsiderTrades

Form 4 for ARQT Arcutis Biotherapeutics, Inc.

Accepted 2022-01-07 00:00:00 ET · period of report 2022-01-05 · accession 0001567619-22-000851 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DM 2022-01-07 2022-01-05 ARQT Watanabe Todd Franklin Pres, CEO, Dir S - Sale+OE $21.59 -1,000 594.8K -0.2% -$21.6K
D 2022-01-07 2022-01-05 ARQT Watanabe Todd Franklin Pres, CEO, Dir M - OptEx $1.68 +1,000 595.8K +0.2% +$1,680
D 2022-01-07 2022-01-05 ARQT Watanabe Todd Franklin Pres, CEO, Dir M - OptEx $0.00 -1,000 120.6K -0.8% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2022-01-05 S D 100 $22.06 595,379 D — — (F2) Includes 54,450 RSUs. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof.
2 Common Common Stock 2022-01-05 S D 300 $22.40 595,479 D — — (F2) Includes 54,450 RSUs. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof.
3 Common Common Stock 2022-01-05 M A 1,000 $1.68 595,779 D — — (F2) Includes 54,450 RSUs. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof.
4 Common Common Stock 2022-01-05 S D 600 $21.11 594,779 D — — (F2) Includes 54,450 RSUs. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof.
5 Derivative Stock Option (Right to Buy) 2022-01-05 M D 1,000 $0.00 120,635 D $1.68 · — to 2029-03-13 1,000 Common Stock (F7) The option began vesting monthly over a four year period beginning upon the achievement of certain company milestones, subject to the Reporting Person's continuous provision of services to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase.